Noninvasive options for ‘wearing-off’ in Parkinson's disease: a clinical consensus from a panel of UK Parkinson's disease specialists
| dc.contributor.author | Carroll, CB | en |
| dc.contributor.author | Fackrell, R | en |
| dc.contributor.author | Grosset, D | en |
| dc.contributor.author | Mohamed, B | en |
| dc.contributor.author | Reddy, P | en |
| dc.contributor.author | Parry, M | en |
| dc.contributor.author | Chaudhuri, K | en |
| dc.contributor.author | Foltynie, T | en |
| dc.date.accessioned | 2018-07-06T11:01:26Z | |
| dc.date.accessioned | 2018-07-09T11:30:16Z | |
| dc.identifier.issn | 1758-2024 | en |
| dc.identifier.uri | http://hdl.handle.net/10026.1/11823 | |
| dc.description.abstract |
In the past 4 years, two adjunctive treatment options to levodopa have been licensed for use in the UK in patients with Parkinson's disease (PD) and motor fluctuations: opicapone, a third-generation catechol-O-methyl transferase inhibitor, and safinamide, a monoamine oxidase B inhibitor. This clinical consensus outlines the practical considerations relating to motor fluctuations and managing wearing-off in patients with PD, and provides a clinical insight to adjunctive treatment options, including opicapone and safinamide. Practice-based opinion was provided from a multidisciplinary steering Group of eight UK-based movement disorder and PD specialists, including neurologists, geriatricians and a nurse specialist, from England, Scotland and Wales. | |
| dc.language.iso | en | en |
| dc.publisher | Future Medicine | en |
| dc.relation.replaces | http://hdl.handle.net/10026.1/11813 | |
| dc.relation.replaces | 10026.1/11813 | |
| dc.relation.replaces | 10026.1/11812 | |
| dc.relation.replaces | http://hdl.handle.net/10026.1/11812 | |
| dc.title | Noninvasive options for ‘wearing-off’ in Parkinson's disease: a clinical consensus from a panel of UK Parkinson's disease specialists | en |
| dc.type | Journal Article | |
| plymouth.journal | Neurodegenerative Disease Management | en |
| pubs.merge-from | 10026.1/11812 | |
| pubs.merge-from | http://hdl.handle.net/10026.1/11812 | |
| plymouth.organisational-group | /Plymouth | |
| plymouth.organisational-group | /Plymouth/Faculty of Health | |
| plymouth.organisational-group | /Plymouth/Faculty of Health/Peninsula Medical School | |
| plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA | |
| plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA/UoA03 Allied Health Professions, Dentistry, Nursing and Pharmacy | |
| plymouth.organisational-group | /Plymouth/Research Groups | |
| plymouth.organisational-group | /Plymouth/Research Groups/FoH - Applied Parkinson's Research | |
| plymouth.organisational-group | /Plymouth/Research Groups/FoH - Community and Primary Care | |
| plymouth.organisational-group | /Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED) | |
| plymouth.organisational-group | /Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED)/CCT&PS | |
| plymouth.organisational-group | /Plymouth/Research Groups/Plymouth Institute of Health and Care Research (PIHR) | |
| plymouth.organisational-group | /Plymouth/Users by role | |
| plymouth.organisational-group | /Plymouth/Users by role/Academics | |
| dcterms.dateAccepted | 2018-06-19 | en |
| dc.rights.embargodate | 2018-08-03 | en |
| dc.rights.embargoperiod | Not known | en |
| rioxxterms.licenseref.uri | http://www.rioxx.net/licenses/all-rights-reserved | en |
| rioxxterms.type | Journal Article/Review | en |
